Cargando…
A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters
Purpose: Ocular floaters caused by vitreous degeneration or blood clots may interfere with various visual functions. Our study investigated the pharmacologic effects of oral supplementation of mixed fruit enzymes (MFEs) for treating spontaneous symptomatic vitreous opacities (SVOs) and those seconda...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695351/ https://www.ncbi.nlm.nih.gov/pubmed/36431188 http://dx.doi.org/10.3390/jcm11226710 |
_version_ | 1784838035504889856 |
---|---|
author | Ma, Jui-Wen Hung, Jen-Lin Takeuchi, Masaru Shieh, Po-Chuen Horng, Chi-Ting |
author_facet | Ma, Jui-Wen Hung, Jen-Lin Takeuchi, Masaru Shieh, Po-Chuen Horng, Chi-Ting |
author_sort | Ma, Jui-Wen |
collection | PubMed |
description | Purpose: Ocular floaters caused by vitreous degeneration or blood clots may interfere with various visual functions. Our study investigated the pharmacologic effects of oral supplementation of mixed fruit enzymes (MFEs) for treating spontaneous symptomatic vitreous opacities (SVOs) and those secondary to vitreous hemorrhage (VH). Methods: 224 patients with monocular symptomatic vitreous opacities (SVOs) were recruited between September and December 2017 and received oral supplementation of MFEs (190 mg bromelain, 95 mg papain, and 95 mg ficin) for 3 months in a double-blind clinical trial. Participants were divided according to the etiology of the SVOs, spontaneous (experiment 1) versus VH (experiment 2), and then randomly assigned into four treatments groups: one group received oral vitamin C, as a placebo; and the other 3 groups received 1 capsule per day (low dose), 2 capsules per day (middle dose), or 3 capsules per day (high dose) of MFEs. The number of SVOs was determined at baseline and then 1, 2, and 3 months after initiating treatment. Further, in cases secondary to VH, the changes in corrected distance visual acuity (CDVA) were assessed after 3 months. Second, we compared the free radical scavenging capabilities of each substance: vitamin C, bromelain, papain, ficin, and MFEs (combination of bromelain, papain, and ficin) by DDPH assay. Finally, SVOs-related symptoms and satisfaction with the treatments were evaluated at the last follow-up visit Results: In experiment 1, the disappearance rate of SVOs was 55%, 62.5%, and 70% after taking 1, 2, and 3 capsules daily, respectively (total p < 0.001), in a dose-dependent manner. In experiment 2, the disappearance rate of VH-induced SVOs was 18%, 25%, and 56% (p < 0.001) after 1, 2, and 3 capsules of the supplement daily, respectively. Additionally, the patients’ vision elevated from 0.63LogMAR to 0.19LogMAR (p = 0.008). Conclusions: A pharmacological approach using a high dose of oral supplementation with MFEs (bromelain, papain, and ficin) was effective in reducing vitreous opacities, even after intraocular hemorrhage. Furthermore, pharmacologic vitreolysis with MFEs supplementation showed high patient satisfaction, and also improved CDVA in patients with vitreous hemorrhage-induced floaters |
format | Online Article Text |
id | pubmed-9695351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96953512022-11-26 A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters Ma, Jui-Wen Hung, Jen-Lin Takeuchi, Masaru Shieh, Po-Chuen Horng, Chi-Ting J Clin Med Article Purpose: Ocular floaters caused by vitreous degeneration or blood clots may interfere with various visual functions. Our study investigated the pharmacologic effects of oral supplementation of mixed fruit enzymes (MFEs) for treating spontaneous symptomatic vitreous opacities (SVOs) and those secondary to vitreous hemorrhage (VH). Methods: 224 patients with monocular symptomatic vitreous opacities (SVOs) were recruited between September and December 2017 and received oral supplementation of MFEs (190 mg bromelain, 95 mg papain, and 95 mg ficin) for 3 months in a double-blind clinical trial. Participants were divided according to the etiology of the SVOs, spontaneous (experiment 1) versus VH (experiment 2), and then randomly assigned into four treatments groups: one group received oral vitamin C, as a placebo; and the other 3 groups received 1 capsule per day (low dose), 2 capsules per day (middle dose), or 3 capsules per day (high dose) of MFEs. The number of SVOs was determined at baseline and then 1, 2, and 3 months after initiating treatment. Further, in cases secondary to VH, the changes in corrected distance visual acuity (CDVA) were assessed after 3 months. Second, we compared the free radical scavenging capabilities of each substance: vitamin C, bromelain, papain, ficin, and MFEs (combination of bromelain, papain, and ficin) by DDPH assay. Finally, SVOs-related symptoms and satisfaction with the treatments were evaluated at the last follow-up visit Results: In experiment 1, the disappearance rate of SVOs was 55%, 62.5%, and 70% after taking 1, 2, and 3 capsules daily, respectively (total p < 0.001), in a dose-dependent manner. In experiment 2, the disappearance rate of VH-induced SVOs was 18%, 25%, and 56% (p < 0.001) after 1, 2, and 3 capsules of the supplement daily, respectively. Additionally, the patients’ vision elevated from 0.63LogMAR to 0.19LogMAR (p = 0.008). Conclusions: A pharmacological approach using a high dose of oral supplementation with MFEs (bromelain, papain, and ficin) was effective in reducing vitreous opacities, even after intraocular hemorrhage. Furthermore, pharmacologic vitreolysis with MFEs supplementation showed high patient satisfaction, and also improved CDVA in patients with vitreous hemorrhage-induced floaters MDPI 2022-11-13 /pmc/articles/PMC9695351/ /pubmed/36431188 http://dx.doi.org/10.3390/jcm11226710 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ma, Jui-Wen Hung, Jen-Lin Takeuchi, Masaru Shieh, Po-Chuen Horng, Chi-Ting A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters |
title | A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters |
title_full | A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters |
title_fullStr | A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters |
title_full_unstemmed | A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters |
title_short | A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters |
title_sort | new pharmacological vitreolysis through the supplement of mixed fruit enzymes for patients with ocular floaters or vitreous hemorrhage-induced floaters |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695351/ https://www.ncbi.nlm.nih.gov/pubmed/36431188 http://dx.doi.org/10.3390/jcm11226710 |
work_keys_str_mv | AT majuiwen anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters AT hungjenlin anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters AT takeuchimasaru anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters AT shiehpochuen anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters AT horngchiting anewpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters AT majuiwen newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters AT hungjenlin newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters AT takeuchimasaru newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters AT shiehpochuen newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters AT horngchiting newpharmacologicalvitreolysisthroughthesupplementofmixedfruitenzymesforpatientswithocularfloatersorvitreoushemorrhageinducedfloaters |